Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines현재 사용 가능한 COVID-19 백신에 저항할 가능성이 있는 새로 분류된 관심 변종인 SARS-CoV-2 Mu에 대처하기 위한 전략Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adopted approach B.1 lineage B.1.621 BNT161b2 booster dose Characteristics coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine COVID-19 vaccine development Evidence exacerbated Genetic genomic Genomic surveillance global mass vaccination Health implementation infections Intervention Lineage mass vaccination Mu variant mutations Neutralizing non-pharmaceutical interventions (NPIs) NPIs potential risk public health measure public health measures Recombination reported required respiratory restrict SARS-CoV-2 SARS-CoV-2 B.1.621 SARS-CoV-2 virus sera shown Strains Strategy sub-lineage B.1.621.1 Surveillance survivor the SARS-CoV-2 virus therapeutic threat vaccination Vaccine vaccine breakthrough. Vaccine development variant variants [DOI] 10.1080/21645515.2022.2027197 PMC 바로가기 [Article Type] Article
Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants코로나바이러스 질병 재조합 소단위 백신의 세 번째 용량으로 이종 부스팅은 다양한 중증 급성 호흡기 증후군 코로나바이러스 2 변이체에 대한 중화 항체 및 T 세포 면역을 증가시킵니다Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis Anti-RBD IgG anti-S booster vaccination CD4+ T cell components composite pattern coronavirus coronavirus disease COVID-19 COVID-19 vaccinations COVID-19 vaccine dose effective epitope Epitopes evaluated Evidence help Heterologous heterologous boosting homologous Humoral immunity Immune escape Immunity immunization strategy immunological in some inactivated Inactivated vaccine increase magnitude NAb NAbs natural infection Neutralizing Neutralizing antibodies neutralizing antibody neutralizing capacity omicron pandemic prime-boost strategy produced RBD IgG respiratory subunit Subunit vaccine Subunit vaccine. T cell T cell response T cells titre vaccination Vaccination strategies Vaccination strategy Vaccine Vaccine-induced immunity variant variants of concern waned [DOI] 10.1080/22221751.2022.2048969 PMC 바로가기 [Article Type] Article
Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections예방접종을 받지 않은 입원 소아에서 SARS-CoV-2 Omicron BA.2 감염의 심각도: 인플루엔자 및 파라인플루엔자 감염과의 비교Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] 95%CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted Admission children Clinical outcome coronavirus COVID-19 COVID-19 infection Croup database death had no hospitalisation hospitalisations Hospitalization Hospitalized Infection Influenza Influenza virus initial investigated Mild neurological Neurological complication Neurological complications occurred omicron outcome parainfluenza parainfluenza virus proportion Public Hospital Relative risk required respiratory. retrieved risk SARS-CoV-2 severe acute respiratory syndrome Coronavirus severity uninfected upper airway upper airways vaccination variant viral infections virus viruses were recorded [DOI] 10.1080/22221751.2022.2093135 PMC 바로가기 [Article Type] Article
SARS-CoV-2 pseudovirus enters the host cells through spike protein-CD147 in an Arf6-dependent mannerSARS-CoV-2 슈도바이러스는 Arf6 의존적 방식으로 스파이크 단백질-CD147을 통해 숙주 세포에 들어갑니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approach Arf6 blockade CD147 cells clathrin Clathrin-mediated endocytosis clinically coronavirus endocytic endocytic mechanism endocytosis evaluate feasible function host cell host cells Huh-7 cell Huh-7 cells independent independent of indicated infected Vero E6 cells Infection inhibited inhibitor knockdown Localization macropinocytosis pathway Prevent pseudovirus pseudovirus infection public health RAB5A SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 pseudovirus SARS-CoV-2 pseudovirus infection severe acute respiratory syndrome Coronavirus Spike protein spike protein. Spread the SARS-CoV-2 variant Vero E6 VERO E6 cells viral infection weakened [DOI] 10.1080/22221751.2022.2059403 PMC 바로가기 [Article Type] Article
SARS-CoV-2 shedding dynamics and transmission in immunosuppressed patients면역 억제 환자의 SARS-CoV-2 발산 역학 및 전파Article Published on 2022-12-012022-09-11 Journal: Virulence [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus adjust analysed anatomic site characterized collected conducted coronavirus Diagnosis Diversity dominant E484K first positive fitness genetic change Genome genomic Host hosts household transmission Immunosuppressed immunosuppressed patient immunosuppressed patients in urine in vivo Infection Interaction knowledge long-term viral shedding mother mutate Mutation mutation dynamics N501Y occurred P681R Patient replicate residue residues SARS-CoV-2 SARS-CoV-2 evolution selective Sequencing severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 specific treatment Spike protein spread to Substitution temporal dynamics Transmission two patients Urine variant variant of concern variants variants of concern virus whole genome Whole genome sequencing whole genome sequencing. whole-genome sequencing [DOI] 10.1080/21505594.2022.2101198 PMC 바로가기 [Article Type] Article
An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entrySARS-CoV-2 S2에서 파생된 조작된 5나선 번들은 바이러스 진입을 억제하기 위해 혈청학적 pH와 엔도솜 pH 모두에서 사베코바이러스 스파이크를 사전 결합합니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] 5-helix bundle (5HB) acute respiratory syndrome acute respiratory syndrome coronavirus bind binding Broad-spectrum inhibition can not cell membrane construction coronavirus Evidence feature fusion heptad repeat highlighting host cell host cells IC50 infections inhibit neutralize peptide peptides pre-fusion predominant Protein sarbecovirus sarbecovirus Sarbecoviruses SARS-CoV-2 SARS-CoV-2 pseudovirus SARS-CoV-2 S2 SARS-CoV-2 variant SARS-CoV-2 variants serological severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 structural basis These data Treatment viral entry viral entry. viral spike virus entry virus infection [DOI] 10.1080/22221751.2022.2095308 PMC 바로가기 [Article Type] Article
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variantsCoronVac 백신 3차 접종은 SARS-CoV-2 Delta 및 Omicron 변이체를 인식하는 광범위하고 강력한 적응 면역 반응 유도Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immune response B cell B cells boost booster booster dose booster vaccination CD4 CD8 Cell circulating comparable contagious CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta demonstrated detectable domain dose effective elevated elicited fold follicular healthy subject helper T cell Humoral immunity IgA responses immune responses Inactivated vaccine individual induce memory B memory B cell memory B cells neutralization neutralization activities neutralization activity neutralization. neutralizing activities omicron Omicron variants peaked predominant preserved Protein RBD receiving recognize reduced remained respiratory response SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 variant significantly increased spike-specific IgG strain subpopulations sustained T cell T cell responses T cells T cells response vaccination variant variants VOCs [DOI] 10.1080/22221751.2022.2081614 PMC 바로가기 [Article Type] Article
Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice근육내 및 비강내 상동 프라임-부스트를 침팬지 아데노바이러스 기반 COVID-19 백신과 결합하면 마우스에서 강력한 체액성 및 세포성 면역 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Adenovirus adenovirus-based Adenovirus-vectored vaccine Administered antibody titres approach BALB/c mice booster Cellular immune response ChAdTS-S coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines cytokine decrease Efficacy elicit elicited evaluated followed by group highest homologous humoral IFN-γ IFN-γ ELISPOT IgA IgG immune immune responses immunogenicity intracellular cytokine staining intramuscular intramuscular vaccination intranasal intranasal. Meso Scale Discovery mice prime immunization priming protocol provide pseudovirus neutralizing antibody respiratory responsible SARS-CoV-2 serotype shown T-cell Response T-cell responses tested titre vaccination Vaccine variants vectored vaccine [DOI] 10.1080/22221751.2022.2097479 PMC 바로가기 [Article Type] Article
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domainSARS-CoV-2 S2 도메인에 대한 항체의 결합 및 중화 능력Article Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody B.1.1.7 B.1.351 B.1.617.2 B.1.621 binding binding activity carried conserved convalescent patient coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 determined by domain ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated Evidence Immune escape immune protection mAb mAbs MERS MERS-CoV Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus molecular monoclonal antibodies monoclonal antibody N Terminal N terminal domain NAbs Neutralization assay neutralization assay. Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody NTD P.1 Protein pseudo-virus RBD Receptor binding domain reported Research respiratory Result S protein S proteins S2 protein S2 subunit SARS-CoV SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 S SARS-CoV-2 S2 SARS-CoV-2 WT Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly specific antibodies subunit target targets terminal Vaccine design variant variants wild-type [DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article
Research progress on vaccine efficacy against SARS-CoV-2 variants of concern우려되는 SARS-CoV-2 변이체에 대한 백신 효능 연구 진행Review Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition caused contributed coronavirus COVID-19 COVID-19 vaccine declined Delta Efficacy Epidemic epidemic wave Epidemics Health Organization Immune escape Measures Neutralizing Neutralizing antibodies omicron Omicron variants pathogenicity Prevention and control Protective Research research and development SARS-CoV-2 SARS-CoV-2 variant severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 triggered vaccination Vaccine vaccine efficacy variant Variant of concern. variants variety VoC VOCs WHO World Health Organization [DOI] 10.1080/21645515.2022.2057161 PMC 바로가기 [Article Type] Review